|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Iterative mouse modeling and comparative oncogenomics analysis show that MYC-overexpression strongly reshapes the CNA landscape of BRCA1-deficient mammary tumors and identify MCL1 as a collaborating driver in these tumors.
|
30674894 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our primary goal is to therapeutically target the oncogenic transcription factor MYC to stop tumor growth and cancer progression.
|
31790487 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
|
30076412 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In a xenotransplant model of diffuse large B-cell lymphoma, the combination of IQS-01.01RS and CPI203 decreased tumor burden through MYC and p-AKT downregulation, and enhanced the induction of apoptosis.
|
29954928 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Because BRCA1 is highly expressed in neuronal progenitor cells during early development<sup>4</sup> and MYC is less efficient than MYCN in recruiting BRCA1, our findings indicate that a cell-lineage-specific stress response enables MYCN-driven tumours to cope with deregulated RNAPII function.
|
30894746 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In conclusion, the tumor cell-macrophage interaction contributes to ATRT-MYC heterogeneity and potentially to tumor recurrence.
|
31848709 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The E3 ligase and tumor suppressor FBW7 targets drivers of cell-cycle progression such as the oncogenic transcription factor c-MYC, for proteasomal degradation.
|
30606768 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Expression of PAX8‑AS1:28, PAX8 and MYC in tumor tissue, adjacent healthy tissue and different cell lines were detected by qRT‑PCR and western blot analysis.
|
30720110 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In vivo knockout of ID3 potentiated the effects of MYC, leading to rapid tumorigenesis and tumor phenotypes consistent with those observed in the human disease.
|
31558468 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our data provide a rationale for clinical evaluation of therapeutic synergy of these two classes of inhibitors in ovarian cancer patients whose tumors show high MYC expression and who do not respond to PARP inhibitors or CDK4/6 inhibitors monotherapies.
|
30898650 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In compound mutant mice, overexpression of c-MYC in an immunodeficient background led to a decreased incidence of CPP and reduced tumour bulk.
|
31142360 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Further analysis on 2 tumors revealed unfavorable histology with MYC protein overexpression but with neither MYCN amplification nor MYCN protein overexpression.
|
29426276 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating MTORC2 activation in esophageal squamous cell carcinoma.
|
31319137 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Although MAX is regarded as an obligate dimerization partner for MYC, its function in normal development and neoplasia is poorly defined.
|
31395740 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Therefore, the deregulation of MYC expression in this setting creates a MYC-dependent normal-to-tumour switch that can be measured <i>in vivo</i> These MYC-driven tumours exhibit classic hallmarks of human breast cancer at both the pathological and molecular level.
|
31350286 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Consistent with the in vitro findings, MYC expression was found to be reduced, while p27 expression was found to be elevated, and BIM expression and cleaved PARP levels were found to be increased in trametinib-treated xenograft tumors.
|
30788663 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest that circCDYL functions as a tumor suppressor in bladder cancer by down-regulating the expression of C-MYC, and this circular RNA might be used as a new target for bladder cancer therapy.
|
30968727 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Fifty-nine (73.8%) of 80 UVM patients showed gains in MYC copy number, and a high MYC copy number was associated with aggressive clinicopathological features of tumors and poor survival.
|
31848373 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We recently identified a subgroup of TNBC with loss of the tumor suppressor PTEN and five specific microRNAs that exhibits exceedingly poor clinical outcome and contains TP53 mutation, RB1 loss and high MYC and WNT signalling.
|
31836816 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition of GCN2 phenocopies eIF2B5 depletion and has therapeutic efficacy in tumour organoids, which demonstrates that a negative MYC-eIF2α feedback loop constitutes a targetable vulnerability of colorectal tumours.
|
31685988 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In addition, the tumour sample of the patient was positive for the classical somatic chromosomal translocation t(8;14) involving the c-MYC gene frequently identified in BL.
|
30569626 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Among the 17 patients with matched tumors, four patients gained PIK3CA amplifications and two patients gained c-MYC amplifications in the recurrent tumors, with no loss of amplification or gain of deletions.
|
30584090 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The 2016 revised World Health Organization (WHO) classification of lymphoid neoplasms included the category of high-grade B cell lymphomas (HGBLs) with combined MYC and BCL2 and/or BCL6 rearrangements (double-hit, DH).
|
30613837 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
ANXA2 high expression tumors enriched DNA repair-related gene sets (DNA repair; P = .011, p53 pathway; P = .036) and cell proliferation-related gene sets (MYC targets; P = .041).
|
31171367 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy.
|
31679823 |
2019 |